Breaking News

CordenPharma to Establish New Peptide Manufacturing Facility in Switzerland

This >€500 million investment will feature multiple manufacturing lines capable of supporting small, medium, and large-scale peptide production.

Author Image

By: Charlie Sternberg

Associate Editor

An aerial sketch of CordenPharma’s future peptide manufacturing facility located at Getec Park in Muttenz, Switzerland. Image courtesy of CordenPharma.

As part of its growth initiatives, CordenPharma has finalized plans to establish a new peptide manufacturing facility in Switzerland located at Getec Park in Muttenz, 8 km outside Basel—a major biotech and pharma hub within Europe. Dr. Michael Quirmbach, President & CEO of CordenPharma Group, said: “We are excited to announce the construction of a state-of-the-art manufacturing plant just outside Basel, Switzerland, within one of the leading pharma and biotech hubs in Europe. The new faci...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters